Johnson & Johnson
JNJJohnson & Johnson (JNJ) is a multinational healthcare company known for its diversified portfolio of pharmaceuticals, medical devices, and consumer health products. Founded in 1886, it has established itself as a leading player in healthcare, with a global presence and a reputation for innovation and quality in the industry.
Dividend History
Investors can expect a dividend payout of $1.34 per share, scheduled to be distributed in 52 days on September 8, 2026
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| September 8, 2026 | $1.34 | 2026-08-25 | 2026-08-25 |
| June 9, 2026 | $1.34 | 2026-05-26 | 2026-05-26 |
| March 10, 2026 | $1.30 | 2026-02-24 | 2026-02-24 |
| December 9, 2025 | $1.30 | 2025-11-25 | 2025-11-25 |
| September 9, 2025 | $1.30 | 2025-08-26 | 2025-08-26 |
Dividends Summary
- Consistent Payer: Johnson & Johnson has rewarded shareholders with 91 dividend payments over the past 22 years.
- Total Returned Value: Investors who held JNJ shares during this period received a total of $69.34 per share in dividend income.
- Latest Payout: The most recent dividend of $1.34/share was paid 39 days ago, on June 9, 2026.
- Yield & Schedule: JNJ currently pays dividends quarterly with an annual yield of 2.09%.
- Dividend Growth: Since 2004, the dividend payout has grown by 458.3%, from $0.24 to $1.34.
- Dividend Reliability: JNJ has maintained or increased its dividend for 91 consecutive payments.
Company News
The iShares Global Healthcare ETF (IXJ) outperformed the Invesco S&P 500 Equal Weight Health Care ETF (RSPH) over the past five years, delivering stronger total returns (1.50% dividend yield vs. 0.70%), lower volatility (beta of 0.56 vs. 0.78), and a shallower maximum drawdown. While both funds charge identical 0.40% expense ratios, IXJ's market-...
Johnson & Johnson experienced a mid-July stock pullback of approximately 2% following earnings results, but analysts view this as a buying opportunity. The company reported strong Q2 results with $25.31B in revenue (up 6.8% YOY), beat EPS expectations at $2.90, and raised full-year guidance. With a diversified portfolio, robust pipeline, upcoming...
Johnson & Johnson reported Q2 earnings that beat analyst estimates but disappointed investors, causing a 3% stock decline. While the company raised 2026 guidance and showed strong performance in key drugs like Darzalex and Tremfya, growth was modest compared to competitors. A concerning 2% decline in Abiomed heart pump sales, potentially linked t...
The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% ...
U.S. stocks extended gains following cooler-than-expected producer price inflation data, with PPI falling 0.3% monthly and 5.5% year-over-year. The Nasdaq futures rose 0.68% as markets scaled back Fed rate hike expectations. However, rising oil prices due to U.S.-Iran tensions pose inflation risks. Key movers included ASML gaining 3% on strong ea...
